Cargando…

Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics

The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibodies of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as for protecting IgG from intracellular catabolism. However, it has now become apparent that the same receptor also binds...

Descripción completa

Detalles Bibliográficos
Autores principales: Sand, Kine Marita Knudsen, Bern, Malin, Nilsen, Jeannette, Noordzij, Hanna Theodora, Sandlie, Inger, Andersen, Jan Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306297/
https://www.ncbi.nlm.nih.gov/pubmed/25674083
http://dx.doi.org/10.3389/fimmu.2014.00682
_version_ 1782354306833317888
author Sand, Kine Marita Knudsen
Bern, Malin
Nilsen, Jeannette
Noordzij, Hanna Theodora
Sandlie, Inger
Andersen, Jan Terje
author_facet Sand, Kine Marita Knudsen
Bern, Malin
Nilsen, Jeannette
Noordzij, Hanna Theodora
Sandlie, Inger
Andersen, Jan Terje
author_sort Sand, Kine Marita Knudsen
collection PubMed
description The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibodies of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as for protecting IgG from intracellular catabolism. However, it has now become apparent that the same receptor also binds albumin and plays a fundamental role in homeostatic regulation of both IgG and albumin, as FcRn is expressed in many different cell types and organs at diverse body sites. Thus, to gain a complete understanding of the biological function of each ligand, and also their distribution in the body, an in-depth characterization of how FcRn binds and regulates the transport of both ligands is necessary. Importantly, such knowledge is also relevant when developing new drugs, as IgG and albumin are increasingly utilized in therapy. This review discusses our current structural and biological understanding of the relationship between FcRn and its ligands, with a particular focus on albumin and design of albumin-based therapeutics.
format Online
Article
Text
id pubmed-4306297
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-43062972015-02-11 Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Sand, Kine Marita Knudsen Bern, Malin Nilsen, Jeannette Noordzij, Hanna Theodora Sandlie, Inger Andersen, Jan Terje Front Immunol Immunology The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibodies of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as for protecting IgG from intracellular catabolism. However, it has now become apparent that the same receptor also binds albumin and plays a fundamental role in homeostatic regulation of both IgG and albumin, as FcRn is expressed in many different cell types and organs at diverse body sites. Thus, to gain a complete understanding of the biological function of each ligand, and also their distribution in the body, an in-depth characterization of how FcRn binds and regulates the transport of both ligands is necessary. Importantly, such knowledge is also relevant when developing new drugs, as IgG and albumin are increasingly utilized in therapy. This review discusses our current structural and biological understanding of the relationship between FcRn and its ligands, with a particular focus on albumin and design of albumin-based therapeutics. Frontiers Media S.A. 2015-01-26 /pmc/articles/PMC4306297/ /pubmed/25674083 http://dx.doi.org/10.3389/fimmu.2014.00682 Text en Copyright © 2015 Sand, Bern, Nilsen, Noordzij, Sandlie and Andersen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Sand, Kine Marita Knudsen
Bern, Malin
Nilsen, Jeannette
Noordzij, Hanna Theodora
Sandlie, Inger
Andersen, Jan Terje
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title_full Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title_fullStr Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title_full_unstemmed Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title_short Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
title_sort unraveling the interaction between fcrn and albumin: opportunities for design of albumin-based therapeutics
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306297/
https://www.ncbi.nlm.nih.gov/pubmed/25674083
http://dx.doi.org/10.3389/fimmu.2014.00682
work_keys_str_mv AT sandkinemaritaknudsen unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics
AT bernmalin unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics
AT nilsenjeannette unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics
AT noordzijhannatheodora unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics
AT sandlieinger unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics
AT andersenjanterje unravelingtheinteractionbetweenfcrnandalbuminopportunitiesfordesignofalbuminbasedtherapeutics